This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish (read more).

Event

Highly Potent Active Pharmaceutical Ingredients

The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future

With over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.

The event will explore current market trends, challenges of correctly assessing hazard, the use of innovative containment solutions to minimize risk and advanced manufacturing processes. In addition, the conference aims to guide attendees through novel regulatory updates for each stage of HPAPI development.

PCI’s Director of Scientific Affairs David O’Connell will be speaking at this event.

Visit the event website here:

Date & Time

13 May 2019 - 14 May 2019 - All Day

Location

Copthorne Tara Hotel
Scarsdale Place, Kensington
London
Greater London
W8 5SY
United Kingdom

Loading Map....

Organization Updates May 2019

PCI is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth. The... View Article

Phase I Clinical Trials in Australia: East Coast, US Seminars

PCI will showcase our expertise in Phase I Clinical Trials in Australia with a series of East Coast, US seminars... View Article

x